Please login to the form below

Not currently logged in

Novartis makes trio of appointments to senior leadership team

Michael Ball, Vas Narasimhan and Andre Wyss take on new roles

Novartis Andre WyssNovartis has made three new appointments to its senior leadership team, handing new roles to Michael Ball, Vas Narasimhan and Andre Wyss.

Ball has been appointed as the new division head and chief executive officer of Alcon, replacing Jeff George, and is set to focus on its surgical and vision care division.

Ball joins the Swiss pharmaceutical company from Hospira, where he served as its chief executive officer from 2011 until late last year. Prior to that he held a series of leadership positions at Allergan before his promotion to president.

Joseph Jimenez, chief executive officer of Novartis, said: “His expertise in ophthalmology, as well as medical devices, will be instrumental to accelerating innovation and growth at Alcon.”

Meanwhile, Novartis has promoted Vas Narasimhan to the newly-created role of global head of drug development and chief medical officer.

Formerly the firm's head of development, Narasimhan will now oversee the drug development functionality for its general medicines, ophthalmology pharmaceuticals, oncology and biosimilars units.

The global head of drug development position has been created in a bid to improve resource allocation and technology standards, while as chief medical officer Narasimhan will be responsible for the company's medical, safety and pharmacovigilance policies.

In addition, Novartis has appointed Andre Wyss (pictured above) as its new president of operations.

Wyss joined Novartis in 1984 as a chemistry apprentice and has since held numerous increasingly senior positions at the company including US country head and president of Novartis Pharmaceuticals Corporation.

Currently head of business services and country president for Switzerland, Wyss will add supervision of the company's integrated technical operations to his responsibilities, as well as overseeing its global public and government affairs.

Ball and Narasimhan will join Wyss as members of Novartis' executive committee.

1st February 2016

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company
Random42 Scientific Communication

Random42 is the world's leading medical animation company. Over the past 25 years we have produced core digital assets for...

Latest intelligence

figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...
The rise of real-world evidence
Demonstrating efficacy and value requires more than clinical trial data...
Digital health
The untapped potential to transform healthcare...